TY  - JOUR
AU  - Hielscher, Thomas
AU  - Sill, Martin
AU  - Sievers, Philipp
AU  - Stichel, Damian
AU  - Brandner, Sebastian
AU  - Jones, David
AU  - von Deimling, Andreas
AU  - Sahm, Felix
AU  - Maas, Sybren L N
TI  - Clinical implementation of integrated molecular-morphologic risk prediction for meningioma.
JO  - Brain pathology
VL  - 33
IS  - 3
SN  - 1015-6305
CY  - Oxford
PB  - Wiley-Blackwell
M1  - DKFZ-2022-02788
SP  - e13132
PY  - 2023
N1  - #EA:C060#LA:B300# / 2023 May;33(3):e13132
AB  - Risk prediction for meningioma tumors was until recently almost exclusively based on morphological features of the tumor. To improve risk prediction, multiple models have been established that incorporate morphological and molecular features for an integrated risk prediction score. One such model is the integrated molecular-morphologic meningioma integrated score (IntS), which allocates points to the histological grade, epigenetic methylation family and specific copy-number variations. After publication of the IntS, questions arose in the neuropathological community about the practical and clinical implementation of the IntS, specifically regarding the calling of CNVs, the applicability of the newly available version (v12.5) of the brain tumor classifier and the need for incorporation of TERT-promoter and CDKN2A/B status analysis in the IntS calculation. To investigate and validate these questions additional analyses of the discovery (n = 514), retrospective validation (n = 184) and prospective validation (n = 287) cohorts used for IntS discovery and validation were performed. Our findings suggest that any loss over 5
KW  - brain tumors (Other)
KW  - meningioma (Other)
KW  - molecular biomarkers (Other)
KW  - risk prediction (Other)
KW  - tumor classification (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36377252
DO  - DOI:10.1111/bpa.13132
UR  - https://inrepo02.dkfz.de/record/182607
ER  -